Overview

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Status:
Active, not recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
Phase:
Phase 3
Details
Lead Sponsor:
Apellis Pharmaceuticals, Inc.